Long‐term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)
暂无分享,去创建一个
K. Peris | K. Papp | C. Ferrándiz | D. Thaçi | J. Crowley | J. Cather | P. Joly | J. Gonçalves | R. Day | Rongdean Chen | K. Shah | Jennifer C. Cather